{
    "2020_Q1": {
        "year": 2020,
        "quarter": 1,
        "date": "2020-04-29T08:00:00-04:00",
        "compliments": [
            {
                "analyst_name": "David Lewis",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Bob Hopkins",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Robbie Marcus",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Vijay Kumar",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Joanne Winch",
                "level": 1,
                "quoted_compliment": "Sure, on the integration front, the largest one, BTG, has performed extremely well during the pandemic. So if you wanna build a pandemic portfolio, you wanna have Therasphear. So Therasphear is doing extremely well, grew I think mid teens in the quarter, taking share and is really not a procedure that can be deferred. So the interventional oncology business broadly is doing well, really driven by Therasphear. So I'd say on the sales piece of it, and they also saw Spec Pharma do quite well. So from a sales standpoint, the BTG portfolio has been more robust than legacy BSC, which is great news. And integration, we got ahead of that pre-pandemic. So we're very much on track with the cost synergies commitment that we've made, which is the summer. And most of that work had already been done and implemented pre-COVID pandemic. There's a few facility closures that we're working through that may be temporarily delayed, but overall I would say the cost synergies are on track, if not ahead of track. And the integration of the commercial teams is really kind of taking place. I think that's all systems go."
            },
            {
                "analyst_name": "Josh Jennings",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Jason Bedford",
                "level": 0,
                "quoted_compliment": ""
            }
        ]
    },
    "2020_Q2": {
        "year": 2020,
        "quarter": 2,
        "date": "2020-07-29T08:00:00-04:00",
        "compliments": [
            {
                "analyst_name": "Bob Hopkins",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "David Lewis",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Larry Beagleson",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Robbie Marcus",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Rick Wise",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Vijay Kumar",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Matt Taylor",
                "level": 1,
                "quoted_compliment": "Hi, thank you for taking the question. So I appreciate all the detail on June and July. This is more than we've gotten from a lot of other companies. And I guess I'm just wondering if your positivity on July is, you think, differentially related to your portfolio, your products, your exposures, or Are we seeing just the benefit of having more hindsight, and do you think that we're seeing more broad recovery through the month for the MedTech space?"
            },
            {
                "analyst_name": "Joanne Winch",
                "level": 0,
                "quoted_compliment": ""
            }
        ]
    },
    "2020_Q3": {
        "year": 2020,
        "quarter": 3,
        "date": "2020-10-28T08:00:00-04:00",
        "compliments": [
            {
                "analyst_name": "David Lewis",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Robert Hopkins",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Vijay Kumar",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Larry Eagleson",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Joanne Lynch",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Robbie Marcus",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Rick Wise",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Matt",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Danielle Antelphi",
                "level": 1,
                "quoted_compliment": "Hey, good morning, everyone. Thank you so much for squeezing me in and congrats on a strong quarter. I have two products related questions. So first on Watchman, you know, one of the things investors are paying attention to is, you know, potential competitor coming to market. And I was hoping maybe you could outline what the most from a competitive perspective are that you've built around the Watchman business that should make us feel okay about the continued growth trajectory there. And I'll just ask my second now. On Exalt-B, given the financial constraints at hospitals, I'm just curious about how quickly that can be the meaningful revenue contributor that it probably ultimately will be. But, you know, hospitals have to work through their current financial duress. And those are my questions. Thanks so much."
            }
        ]
    },
    "2020_Q4": {
        "year": 2020,
        "quarter": 4,
        "date": "2021-02-03T08:00:00-05:00",
        "compliments": [
            {
                "analyst_name": "Bob Hopkins",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "David Lewis",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Larry Beagleson",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Joanne Winch",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Robbie Marcus",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Matt Taylor",
                "level": 0,
                "quoted_compliment": ""
            }
        ]
    },
    "2021_Q1": {
        "year": 2021,
        "quarter": 1,
        "date": "2021-04-28T08:00:00-04:00",
        "compliments": [
            {
                "analyst_name": "Bob Hopkins",
                "level": 1,
                "quoted_compliment": "Oh, thank you and good morning and congrats on a good start to the year."
            },
            {
                "analyst_name": "Robbie Marcus",
                "level": 1,
                "quoted_compliment": "Oh, great. And I'll add my congrats on a really strong first quarter here."
            },
            {
                "analyst_name": "Larry Beagleson",
                "level": 1,
                "quoted_compliment": "Good morning. Thanks for taking the questions and congrats on the really nice quarter here."
            },
            {
                "analyst_name": "Vijay Kumar",
                "level": 1,
                "quoted_compliment": "Hey, guys. Congrats on the nice brings here."
            },
            {
                "analyst_name": "Kyla Kroom",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Cecilia Furlong",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Rick Wise",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Matt Mixick",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Josh Jennings",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Danielle Antelfi",
                "level": 1,
                "quoted_compliment": "Hey, good morning, everyone. Thanks so much for taking the question. Congrats on a really strong start to the year."
            }
        ]
    },
    "2021_Q2": {
        "year": 2021,
        "quarter": 2,
        "date": "2021-07-27T08:00:00-04:00",
        "compliments": [
            {
                "analyst_name": "Bob Hopkins",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Robbie Marcus",
                "level": 1,
                "quoted_compliment": "Great. I'll add my congratulations on a really nice quarter. Two for me. First, it looks like you had great growth in the US with 12% organic over 2019. I was wondering You know, maybe you could just give us an overview of where you're seeing the recovery. Are you seeing any lagging trends from Delta variant? And is there any discrepancy in inpatient versus outpatient? You're one of the first to report here with such a global covering and diverse offering. I think it'd be really instructful as we think about the rest of the year and the guidance."
            },
            {
                "analyst_name": "Larry Beagleson",
                "level": 1,
                "quoted_compliment": "Please go ahead. Good morning. Thanks for taking the questions and congrats on the quarter and congrats to Lauren. Just one follow-up on the investor meeting in September. Maybe Dan or Mike, just level set us kind of what we should expect. Will you provide an update to your financial goals and pipeline and any reason to think the algorithm of 6% to 8% sales and You know, 50 to 100 basis points margin improvement with double-digit EPS growth has changed, and I had one follow-up."
            },
            {
                "analyst_name": "BJ Kumar",
                "level": 1,
                "quoted_compliment": "Hi, Mike. Congrats on the quarter here. Thanks for taking my question. One on a high level. If I just look at the 2Q performance and the back half implied guide, you know, we did 9% in 2Q versus pre-pandemic 2019. Back half implied is 7 and 9. I mean, we're already running, if I look at the 2Q to 4Q performance, we're already running well north of 8%. Preventus, Lumenis, once these deals become organic, they should be incremental, plus you have these pipelines. I guess when I look at that LRP of 6 to 8, shouldn't these results provide a high degree of confidence in upper end of that LRP on the top line going forward?"
            },
            {
                "analyst_name": "Cecilia Furlong",
                "level": 1,
                "quoted_compliment": "Great. Good morning and thanks for taking our questions. I wanted to ask about SCS trialing trends and really just what you've seen from a relative recovery versus other more elective procedures in the quarter and then kind of tying in also just VertiFlex, what type of traction you've seen recently?"
            },
            {
                "analyst_name": "Peter Chickening",
                "level": 1,
                "quoted_compliment": "Hey, good morning, guys. Thanks for taking my questions. Congrats on a nice quarter and also congrats to Lauren. To follow up on Bob's question, I understand the comps versus 2018 for 3Q is challenging at 9%, but we also heard from the public hospitals that June was the best month of the quarter and strong June trends continue into July. So just curious, as you look at your third quarter guidance, are you seeing normal 3Q seasonality, or are you simply assuming that you'll see it at some point during the quarter?"
            },
            {
                "analyst_name": "Joanne Wunsch",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Travis Steed",
                "level": 0,
                "quoted_compliment": ""
            }
        ]
    },
    "2021_Q3": {
        "year": 2021,
        "quarter": 3,
        "date": "2021-10-27T08:00:00-04:00",
        "compliments": [
            {
                "analyst_name": "Bob Hopkins",
                "level": 1,
                "quoted_compliment": "Yeah, so if you think about that, you take a step back and look at third quarter, and that's why I started my script that I'm really proud of the team's global execution. Because if you think about it, we went through a delta surge in the third quarter, which was bigger than most anybody anticipated. And we grew 11% versus 20% and 4% versus 19%. Now, 4% is not a great number, but it's not a bad number, growing 4% given the delta surge. And during that time, we had nice improvement in operating income margin, despite some of the supply chain headwinds that everyone's familiar with. And we delivered our EPS growth. So in a quarter where Delta surged, we grew top line fairly well, clearly not where we want it to be in normal situations, but we improved margins. We hit EPS. And in the third quarter, we have all those macro issues you talked about, but we do anticipate moving forward that You know, the impact on COVID in the company when it surges has decreased upon each surge. So every time there's been a Delta surge, the performance, although not where we want it to be, has been better each time. And so that shows the hospital's ability to manage COVID. You know, one great thing about our portfolio was we're primarily an interventional medicine company. And I was at a couple sites just yesterday, and they're doing 80% of their Watchman volume outpatient now. So you've seen a dramatic shift in Watchman, for example, outpatient procedures. So I think our portfolio has tailwinds that support productivity for hospitals. Hospitals have shown the ability to execute despite surges. And in a quarter where about every macro issue was thrown on top of the company, I think the performance is quite good."
            },
            {
                "analyst_name": "Robbie Marcus",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Joanne Wench",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Rick Wise",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Vijay Kumar",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Danielle Antofi",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Matthew O'Brien",
                "level": 1,
                "quoted_compliment": "Yeah, Mike, as I look across the portfolio, I think a lot of things held up better than I might've expected going into Q3 with all these, these COVID headwinds, you know, with, with their sphere doing better and peripheral and, and, um, uh, preventive seeming to hold up, you know, CRM and Watchman obviously doing well, even when netting out the, um, the reserve tailwind. So what I'm curious about is what you're seeing in non COVID geographies, as far as the momentum in those businesses, You know, are you taking share with some of these new products? Are you seeing accelerating momentum with some of these new categories? And why wouldn't that accelerate coming out of COVID just given, you know, some of the underlying strength that I think is there?"
            },
            {
                "analyst_name": "Anthony Petroni",
                "level": 0,
                "quoted_compliment": ""
            }
        ]
    },
    "2021_Q4": {
        "year": 2021,
        "quarter": 4,
        "date": "2022-02-02T08:00:00-05:00",
        "compliments": [
            {
                "analyst_name": "Robbie Marcus",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Larry Beagleson",
                "level": 1,
                "quoted_compliment": "Good morning. Thanks for taking the question and congrats on a nice finish to the year. Just on Watchman. Yeah, of course. Just on Watchman, just what you've seen so far with Amulet, you know, Boston, I mean, I'm sorry, Habit claims they had about 10% share in the U.S. in December. What are you assuming in the guidance, you know, for Watchman growth in 2022? And, you know, how confident are you you'll get the DAP label in the first half of this year? Thanks for taking the question."
            },
            {
                "analyst_name": "Joanne Lynch",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Vijay Kumar",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Danielle Antalfi",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Matt Mixick",
                "level": 1,
                "quoted_compliment": "Hi, good morning. Thanks for taking the question. So I had one follow-up on some of the portfolio and investment and strategic comments that you made regarding Millipede and sort of the other options that are out there. If you could talk maybe a little bit about one of the areas I don't think you mentioned was tricuspid and other sort of structural heart opportunities as well as digital and any understanding heart logic is a big part of your CRM strategy. Maybe if you could comment on further investments there or to what degree you view either one of those as strategically important and I had one follow-up if I could."
            },
            {
                "analyst_name": "Matt Taylor",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Cecilia Furlong",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Pito Chickering",
                "level": 0,
                "quoted_compliment": ""
            }
        ]
    },
    "2022_Q1": {
        "year": 2022,
        "quarter": 1,
        "date": "2022-04-27T08:00:00-04:00",
        "compliments": [
            {
                "analyst_name": "Robbie Marcus",
                "level": 1,
                "quoted_compliment": "Good morning, and congrats on a nice quarter. Thanks, Robbie. Maybe to start, you know, it's great to see the outperformance in a tough quarter and the organic sales guidance raise. I was hoping... Maybe you could just walk us through the thought process of coming up with the second quarter guide, which came in maybe just a hair below where the street was. I imagine the China lockdowns are impacting that, if you could comment, and just how you're thinking about the balance of the year and what's assumed."
            },
            {
                "analyst_name": "Rick Wise",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Joanne Winch",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Larry Beagleson",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Vijay Kumar",
                "level": 1,
                "quoted_compliment": "Hey, guys. Hey, guys. Congrats on a nice Q1 print share. My first question, one on guidance here. Dan, Q1 organic bid by 200 basis points, so it looks like the guide rates for annual just annualized the Q1 bid. Any reason why? The Q1 strength would insist in, you know, what specifically are you assuming for China impact? You know, similarly on EPS. It was raised by one cent at the low end, right, given the debt-free-fied bail list. Looks like operating margin is in line-ish. Maybe talk about the annual guidance for a second."
            },
            {
                "analyst_name": "Travis Steed",
                "level": 1,
                "quoted_compliment": "Hi, good morning. Congrats on a good start to the year. Question on the $300 million of anchor, or the headwind that you built in on freight and direct materials versus pre-COVID levels. How much of this is incremental versus the prior guide three months ago? Just trying to get a sense for the rate of change on some of these inflationary pressures, and also try to get a sense for how much of this is actually locked into the P&L for sure versus the potential for some things to actually improve versus what you built in."
            },
            {
                "analyst_name": "Danielle Antalfi",
                "level": 1,
                "quoted_compliment": "Hey, good morning, everyone. Thanks so much for taking the question, and congrats on a really good quarter. I just wanted to get a sense... Yeah, no, thank you. I just wanted to get a sense of the recovery within the quarter, and I just wanted to bounce something off you and see how this will translate to the rest of the year. So our sense from reports to date and from talking to some other privately held companies is that the first half of the quarter, you saw suppressed procedure volumes, then a quick rebound, and everything got compressed. into the quarter within itself the um compressed procedure trends i'm sorry suppressed procedure trends and then the recovery whereas previously it was like down one quarter the recovery the next quarter do you guys think you saw that is my first question and then as we think about the rest of the year and potentially more covid waves do you think the recovery from here is going to look more like that or there's risk excuse me of the volatility that we saw previously i guess what i'm getting at is Is there still a backlog of patients, number one? Number two, do we think this is going to be more consistent, more linear going forward? Sorry, that was a long question."
            },
            {
                "analyst_name": "Cecilia Furlong",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Matthew O'Brien",
                "level": 0,
                "quoted_compliment": ""
            }
        ]
    },
    "2022_Q2": {
        "year": 2022,
        "quarter": 2,
        "date": "2022-07-27T08:00:00-04:00",
        "compliments": [
            {
                "analyst_name": "Jason Bedford",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Joanne Lynch",
                "level": 1,
                "quoted_compliment": "Good morning, and thank you for taking the question. May I say congratulations? I want to spend just a little bit of time on the organic growth rate, because when you entered the year, we were looking for 6% to 8%, which was raised on the first quarter call to 6.5% to 8.5%, and now to 8% to 9% organic. What is happening in your core businesses or in your particular franchises, maybe, that's helping you sort of buck the trend and actually be raising your organic growth rate each quarter?"
            },
            {
                "analyst_name": "Robbie Marcus",
                "level": 1,
                "quoted_compliment": "Oh, great. Thanks for taking the question. I'll add my congratulations on a good quarter. Thanks, Robbie. Dan, I was wondering, it sounds like you're absorbing about 300 basis points of headwinds versus 2019, but on track to generate flat operating margins, which is really impressive given all the headwinds. Maybe just walk through where you're seeing those pressures and you know, how you're offsetting it in the base business. And then if there's anything we should be focused on that carries over into 2023 in the models from some of these offsets or pressures. Thanks."
            },
            {
                "analyst_name": "Larry Diegelson",
                "level": 1,
                "quoted_compliment": "Good morning. Thanks for taking the questions and congrats on a nice quarter. You know, I heard you mention that you are having an analyst meeting at TCT. So, are you expecting to present any significant data there? So, for example, the Saval, you know, BTK data. And if so, kind of what should we be looking for in your confidence you can overcome, you know, the issues of previous devices? And just maybe on Devoro, any color on the launch there and how you see that fitting into the treatment armamentarium. Thanks for taking the question."
            },
            {
                "analyst_name": "Vijay Kumar",
                "level": 1,
                "quoted_compliment": "Hey, guys. Congrats on the print share, and thanks for taking my question. I have a two-part question. One, just on the guidance here, first half versus second half, the high end implies, I think, low doubles in the second half versus 8% in first half. You know, the pre-pandemic comps, you know, first half, second half, 21 versus 19, they seem comparable. There was no first half versus second half. So I'm curious, what's driving the second half acceleration? You know, what was the China lockdown and contrast media impact in 2Q? Perhaps is that what's giving you the confidence looking at the underlying trends for second half? And then on the gross margin, $375 million of cost, do you know what â€“ What dollar amount of that is capitalized on the balance sheet? Thank you."
            },
            {
                "analyst_name": "Rick Wise",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Cecilia Furlong",
                "level": 1,
                "quoted_compliment": "Great. Thank you for taking the question. I wanted to ask on Watchmen, but specifically contrast supply, if you could just talk to the headwind that posed in the quarter. And then, Bradley, too, can you speak to what you've seen from a residual staffing shortage impact across the hospital system at this point? Where do you feel we are in recovery, and how much further recovery is incorporated in your outlook for the back half of the year? And thank you for taking the question."
            },
            {
                "analyst_name": "Travis Steed",
                "level": 1,
                "quoted_compliment": "thank you the next question comes from travis steed with bank of america please go ahead hey good morning congrats on a good quarter uh so you talked about the gross margin pressures being offset in the p l just curious how sustainable that is as you move into 23 does some of that opex have to come back or can you keep opex this level until the gross margin pressures ease and then a quick follow-up on on china up nine percent much better than your peers which are still down Just curious what's driving the strength in your China business versus peers? Thank you."
            },
            {
                "analyst_name": "Pito Chickering",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Josh Jennings",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Richard Newiter",
                "level": 1,
                "quoted_compliment": "Hi. Thanks for taking the questions and congrats on the quarter. You have some competitors out there that are calling out pricing strategies, particularly to head into 2023. Anything you'd call out there potentially as a lever to offset margin headwinds or sustain? And then also, if you could just comment a little bit more on the double-digit growth comment in the back half that you're expecting out of your Neuromod business? Any specific regions driving that? I'm assuming that doesn't assume a major pickup in SES, but other product categories, but please correct that if that's wrong. Thank you."
            },
            {
                "analyst_name": "Shagun Singh",
                "level": 0,
                "quoted_compliment": ""
            }
        ]
    },
    "2022_Q3": {
        "year": 2022,
        "quarter": 3,
        "date": "2022-10-26T08:00:00-04:00",
        "compliments": [
            {
                "analyst_name": "Robbie Marcus",
                "level": 1,
                "quoted_compliment": "Robbie Marcus Great. Thanks for taking the question, and congrats on a great top-line quarter. I'll also add congratulations to Dr. Meredith on a very well-deserved retirement. Maybe for my question, it really was a strong top line, double digits, organic. Fourth quarter continues to look good in guidance. I think the one area where we're seeing a little pressure is on margins. So, Dan, I was hoping you might be able to give us an early look into next year. How elevated is the spending? There's a lot of moving pieces with OpEx and currency and the share count. You know, do you think the street's generally in a decent spot for next year with returning to more normalized margin expansion, or do you think it's still going to be a pressured year in 2023? Thanks."
            },
            {
                "analyst_name": "Larry Bigelson",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Joanne Lynch",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Vijay Kumar",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Travis Seed",
                "level": 1,
                "quoted_compliment": "Travis Seed Hey, thanks for taking the question, and also congrats to Ian Meredith. I might have missed it earlier, but can you remind us again the moving parts on what drove the higher OPX and the lower margin guide for 2022 versus three months ago, just as a quick clarification? And then the question I was going to ask was more on the analyst day last year, you were committed to a double-digit EPS growth CAGR. This year, you're close to 7%. Is that double-digit EPS CAGR still good and the starting point for 2023? and still be in that double-digit range given the macro pressures that we're in?"
            },
            {
                "analyst_name": "Cecilia Furlong",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Rick Wise",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Matthew O'Brien",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Matt Taylor",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Tito Chickering",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Chris Pasquale",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Matt Mixick",
                "level": 1,
                "quoted_compliment": "Matt Mixick Hey, thanks so much for squeezing me in. Hey, how are you? So congrats on a really strong quarter, and Dr. Meredith, we'll certainly miss your insights and your cheerful disposition. And I guess I'm thankful that I've got about six months to get to know this humorous side that everyone's referring to. So I look forward to that. Just one follow-up, if I could, on margins. Dan, you talked about the impact of FX, and it seems like that explains pretty much the three-cent reduction in EPS guide for the year. Just maybe one question on trajectory. There's such a strong Q3 here. You're adjusting Q4 for EPS and top end of the range for organic growth. That strikes me as a little bit conservative, just given the strengths, but love your comment on that. And then maybe you're not talking much about 23, but the shape of margins. I know there's been a lot of questions around how far into 23 some of the higher costs will go and If we were to think about, is that sort of a front half, back half that we should be thinking about for 23 at this point, or I'm sure it's too early to say, but any insight you can give on how we should think about costs as they roll through inventory and P&L and so on. Thanks so much."
            }
        ]
    },
    "2022_Q4": {
        "year": 2022,
        "quarter": 4,
        "date": "2023-02-01T08:00:00-05:00",
        "compliments": [
            {
                "analyst_name": "Rick Wise",
                "level": 1,
                "quoted_compliment": "Good morning, everybody. Great to see another excellent year from Boston Scientific. I guess to focus on one question, I'll start with your 2023 guidance. Obviously, the 6% to 8% guide is right in line with your long-term philosophy, but you started at the same place in 2022, obviously excluding the Italy issue, finished above 9% organically. Why, again, stick with the 6% to 8% Is this conservatism, respect for lingering macro pressures, or both? And maybe just as part of that, why model macro headwinds similar to 22? The large cap companies reporting to date, they're not Boston Scientific, but they're all in some way, shape, or form highlighting the improving or less pressures from macro as they finish the year and start 23. Thank you very much."
            },
            {
                "analyst_name": "Robbie Marcus",
                "level": 1,
                "quoted_compliment": "Oh, great. Thanks for taking the questions, and congrats on a nice quarter. Thanks, Robbie. Maybe to start, Mike, at our conference last month, you were really bullish on Farapulse. And we saw EP have a nice beat in the quarter, particularly outside the U.S., where you have Farapulse and PolarRx going now. Maybe you could talk about your expectations or what you saw in the quarter for Farapulse specifically and your expectations for it in 2023, especially now. after we get the data later in the back half of the year, assuming it looks good?"
            },
            {
                "analyst_name": "Larry Beagleson",
                "level": 1,
                "quoted_compliment": "Good morning. Thanks for taking the question, and congratulations on a strong end to the year here. I wanted to ask a two-part question also on Farrapulse. So maybe for Dr. Stein, you know, you talked about your, you know, excitement for the ADVENT trial later this year. Can you help put the manifest PF data into context? You know, how did that compare to prior RF and cryo studies? And what would be a win for you in Advent, you know, for Farrah Pulse? And we're going to see, the second part is we're going to see the Medtronic Pulse Select data at ACC, the J&J Inspire data at Boston AF, I guess, this weekend. You talked about how Farrah Pulse is differentiated. What should we be looking for in those studies that would support, you know, your comments earlier? Thanks for taking the questions."
            },
            {
                "analyst_name": "Joanne Lynch",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Vijay Kumar",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Travis Seed",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Cecilia Furlong",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Josh Jennings",
                "level": 0,
                "quoted_compliment": ""
            }
        ]
    },
    "2023_Q1": {
        "year": 2023,
        "quarter": 1,
        "date": "2023-04-26T08:00:00-04:00",
        "compliments": [
            {
                "analyst_name": "Robbie Marcus",
                "level": 1,
                "quoted_compliment": "Oh, great. Good morning, and congrats on a great quarter here. Thanks, Robbie. Let me start with, and I'll just ask one two-part question here. Great, great performance in the first quarter, particularly on the top line. We all know this is probably the last easy comp from COVID trends in first quarter last year. But would love to get a sense of, you know, what are you seeing globally? How sustainable is this? You know, you guided to a slight deceleration second quarter. Anything to note there other than conservatism? And then second, you know, there have been some news reports lately about M&A on the behalf of Boston Scientific. We'd love to just get a refresh on your M&A strategy. We've seen a lot more smaller tuck-in type deals historically. You know, is that still the goal? And any thoughts there? Thanks a lot."
            },
            {
                "analyst_name": "Joanne Wench",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Rick Wise",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Larry Bigelson",
                "level": 1,
                "quoted_compliment": "Good morning. Congrats on a great start to the year here, guys. So one for Dr. Stein, one for Mike. So Dr. Stein, you know, Farrapulse is a single shot technology, you know, with PFA energy, you know, but companies are developing large focal catheters and dual energy sources. How are you thinking about the evolution of Farrapulse, you know, beyond its current geometry and energy source? And Mike, you know, we all completely understand you won't comment on rumors, but, you know, there are interesting assets in medtech that would you know, push you to over four and a half times leverage or require the use of equity to relatively large deals. You know, are those options on the table? And just remind us of how you think about ROIC. Thank you."
            },
            {
                "analyst_name": "Travis Speed",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Vijay Kumar",
                "level": 1,
                "quoted_compliment": "Hey, guys. Congrats on the printing. Thanks for taking my question. I had a two-part, one product and one capital allocation. On the product side, PFA, Mike, did I hear it correctly? uh, on the prior question on, on, uh, Sarah calls, uh, can it do point by point, uh, ablation at this point? I thought it was single shot, um, uh, cancer, but I would be curious to know, uh, if you have, if it can do point by point ablation and, and, uh, are you gaining share in the RF side as well, uh, in the current market? Um, and then on, on the capital allocation side, um, I know you're not going to comment on market speculation, so this is not related to market speculation, but can you just remind us, in current interest rate environment, what kind of leverage levels would Boston be comfortable with? And if Boston deems a deal as strategic, would it be okay doing an earnings dilute appeal?"
            },
            {
                "analyst_name": "Danielle Antoloffi",
                "level": 1,
                "quoted_compliment": "Thanks so much. Good morning, everyone, and congrats on a really strong quarter. Just a question on Farrah Pulse. Sorry, there's so much focus on this one product on the call, but I'm curious about how you guys are thinking about the evolution of the market broadly. I mean, this has been a market, the AF ablation market, that's been a double-digit grower for the last decade plus. But is it right to think about Farrah Pulse and just the advent of pulse field ablation overall as potentially accelerating market growth in a meaningfully and sustainable way? because of the safety profile of the device, or how are you thinking about, and what are you seeing, I guess, in Europe about market growth overall for this device? And I have one follow-up on Watchman."
            },
            {
                "analyst_name": "Cecilia Furlong",
                "level": 1,
                "quoted_compliment": "Great. Good morning, and thanks for taking the question and also echoing my congrats on the quarter. I wanted to ask specifically just your comments on pain and SES, really what you saw in the quarter, especially as it pertains to recent headwinds prior auth, and then just your outlook in terms of underlying market growth. Did we see some recapture in one queue? Was that part of the strength in how you're thinking about underlying market growth going forward?"
            },
            {
                "analyst_name": "Matt Taylor",
                "level": 1,
                "quoted_compliment": "Good morning. Thanks for taking the question. So, great result. I guess what I'm struggling to understand is, you know, obviously you saw strong demand in the quarter, and I think we're seeing a lot of macro things improving, like staffing, et cetera. I mean, couldn't it actually theoretically get better sequentially? Why are we thinking so conservatively? Do you think that the direction of travel could be positive, negative, or neutral? And what are some of the background thoughts that you would base that on?"
            },
            {
                "analyst_name": "Matt Mixick",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Chris Pasquale",
                "level": 0,
                "quoted_compliment": ""
            }
        ]
    },
    "2023_Q2": {
        "year": 2023,
        "quarter": 2,
        "date": "2023-07-27T07:30:00-04:00",
        "compliments": [
            {
                "analyst_name": "Robbie Marcus",
                "level": 1,
                "quoted_compliment": "Oh, good morning, and congrats on a really nice quarter. Thanks, Robbie."
            },
            {
                "analyst_name": "Rick Wise",
                "level": 1,
                "quoted_compliment": "Hey, thanks so much for taking the questions, and congrats on a super strong quarter. So really impressed with you breaking it to double digits. You're very welcome. So, Dan, I want to just follow up on cash flows and cash flow conversion. and sort of what the puts and takes there have been in the first half, what your expectations are in the back half, and your intermediate long-term goals there, which we'll talk more about at the analyst meeting. But anything you can share now, and then also just on cash, if I could, you know, you have so many things going on in the portfolio and in your clinical programs, but I'd love to get your sort of posture on the business development front and in your efforts to find and invest in additional technology and assets. Thanks."
            },
            {
                "analyst_name": "Joanne",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Larry Pilsen",
                "level": 1,
                "quoted_compliment": "Good morning. Thanks for taking the question, and I'll reiterate my congratulations on another strong quarter here. Dr. Stein, on Advent, just using the same definition of success in Advent as manifest, I think the success rate was 74%. So what differences do we need to consider between the two studies, and how much do you think those differences could impact the results for Farrapulse. And separately, what have the success rates been with RF and cryo in previous studies when using the same criteria as ADVENT? And sorry for the long question. Just lastly, if Farrapulse is numerically lower on success or efficacy versus RF and cryo, how do you think it will impact adoption? Thanks for taking the question."
            },
            {
                "analyst_name": "Travis Steed",
                "level": 1,
                "quoted_compliment": "Hey, congrats on the good quarter. Just maybe following up to Larry's question, how would you frame up a commercial opportunity for Farrah Paltz for the market growth and share kind of based on the various potential outcomes for Advent? And I think you said it's the most exciting product launch in your career, but just curious how you think the commercial opportunity frames out based on how Advent comes out. And then I'm curious if you've seen the data yet or are you still blinded to the data? Thanks."
            },
            {
                "analyst_name": "Danielle Antofi",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Sam Kurtz",
                "level": 1,
                "quoted_compliment": "Hi, this is Sam Kurtz on for Matt. Congrats on a great quarter and for taking our question. I guess we would like to touch on the guidance again, and maybe could you tell us a little bit about where you're most excited heading into the second half of the year and where we could potentially see that upside?"
            },
            {
                "analyst_name": "Matt Taylor",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Marie",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Patrick Wood",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Vijay Kumar",
                "level": 1,
                "quoted_compliment": "Hey, guys. Thanks for taking my question. Maybe my first one here, if you look at 2023, W organic, that's a pretty big number. Should we worry about comps? When you look at the outlook here, Can you just remind us the plus and minuses from a product perspective? What could be Talvin's headwinds in fiscal 24?"
            },
            {
                "analyst_name": "Jason Bedford",
                "level": 0,
                "quoted_compliment": ""
            }
        ]
    },
    "2023_Q3": {
        "year": 2023,
        "quarter": 3,
        "date": "2023-10-26T08:00:00-04:00",
        "compliments": [
            {
                "analyst_name": "Robin Marcus",
                "level": 1,
                "quoted_compliment": "Hi, good morning, and congrats on a great quarter. And since many of us are at TCT, I'll add the nice agent DCP trial as well. I had two questions. I had two questions, so I'll just go with one here. As we go back to the analyst day, you pointed to 8% to 10% growth and 150 basis points of operating margin expansion over the three-year time frame. And I believe one of the comments was at the beginning of the range, it'll be towards the lower end and accelerate as you have some of your big new product launches coming. So I'm looking at 2024 here, and I see the street at 8% to 9% organic sales growth and about 50 basis points margin expansion. I just want to make sure we're interpreting the comments you made at the end correctly and any thoughts you have on directionality for next year. Thanks a lot."
            },
            {
                "analyst_name": "Joanne Wunsch",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Rick Wise",
                "level": 1,
                "quoted_compliment": "Good morning. Thank you for the question, and it's wonderful to see such an excellent quarter. I guess if I focus on one, maybe you could expand on your, Mike, on your, if you want to do it, your Neuromod comments, just your latest thinking Just broadly, what's going to help re-accelerate the business or what's next from here? But more specifically, the PDN indication approval, how does that affect the business? When does it start contributing? How would you have us think about the beneficial contribution there? Thanks a lot."
            },
            {
                "analyst_name": "BJ Kumar",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Larry Bigleton",
                "level": 1,
                "quoted_compliment": "Good morning. Congrats on the print. Mike, we made it this far without a GLP-1 question, but I'm going to ask it anyway. Obviously, diabetes and obesity are risk factors for many diseases, such as cardiovascular disease. So how are you thinking about the potential long-term impact of GLP-1s on your businesses? And any high-level thoughts, Mike, on how investors have reacted to GLP-1s in general? Thank you."
            },
            {
                "analyst_name": "Travis Steed",
                "level": 1,
                "quoted_compliment": "Great. Thanks a lot for the question. You're asking a good quarter. Thanks, Travis."
            },
            {
                "analyst_name": "Daniel Antalfa",
                "level": 1,
                "quoted_compliment": "Hey, good morning, everyone. Thanks so much for taking the question. And congrats on a great quarter and the data here at TCT. Just a quick question on 2.4 top line guide. I imagine there's some conservatism baked in here, but if I'm looking at it correctly, it is implying a little bit of a deceleration and not to be nitpicky here, but just want to make sure we're understanding of what the tailwinds versus headwinds are as we go into Q4 and heading into 2024. Thanks so much."
            },
            {
                "analyst_name": "Matt Taylor",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Josh Jennings",
                "level": 1,
                "quoted_compliment": "Hi, good morning. Congratulations on the strong results. I wanted to follow up on Travis's question on FerriPulse. I was hoping to just better understand where your US EP sales force stands today and how you're building that out or plan to build that out for the FerriPulse launch. And then just on top of that, just thinking about the full integration of FerroPulse into arrhythmia and developing these Fairview capabilities, is there anything of note that we should be thinking about that would provide clinical advantages that could catalyze stronger demand for arrhythmia once that integration is complete, I believe, at the year end of 24? Thanks for taking the questions."
            },
            {
                "analyst_name": "Chris Pascal",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Michael Pollark",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Matthew O'Brien",
                "level": 0,
                "quoted_compliment": ""
            }
        ]
    },
    "2023_Q4": {
        "year": 2023,
        "quarter": 4,
        "date": "2024-01-31T08:00:00-05:00",
        "compliments": [
            {
                "analyst_name": "Robbie Marcus",
                "level": 1,
                "quoted_compliment": "Oh, great. Congrats on a really good quarter and congratulations, Lauren, on the promotion. I wanted to ask on two of the biggest product drivers in 2024, Watchman and Farapulse. Farapulse got approval today. I wanted to see what's included in guidance for this year and how to think about phasing over the year, how long will it take to get into hospitals and approved on formularies. And then second on Watchman, it still had a very good quarter and fourth quarter, but growth slowed a little bit. How should we be thinking about the potential for Watchmen and 20% plus growth in 2024? Thanks a lot."
            },
            {
                "analyst_name": "Joanne Lynch",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Larry Beagleson",
                "level": 1,
                "quoted_compliment": "Good morning. Thanks for taking the questions. Congrats on a strong finish here and the approval of Farrah Pulse in the U.S. On Farrah Pulse, can you talk about the manufacturing capacity for the Catherine console upon launch and expectations for the EP business this year? You grew 43% in Q4 of 23. Any reason why growth would be lower in 24? And I have to ask you to please clarify your comments around AccurateNEO2. It sounds like something happened with Prime, which is the larger size. What are the implications for the other sizes of NEO2 in Europe and the U.S.? Thank you."
            },
            {
                "analyst_name": "Vijay Kumar",
                "level": 1,
                "quoted_compliment": "Hey, guys. Thanks for taking my question, and congrats on a really strong finish here. Maybe just one on that. the guidance here perhaps for Dan. Dan, the 8% to 9%, it looks like Farrah Paul's, the prior guided assumed back half launch, it's coming in a little bit ahead. Can you just walk us through that 8% to 9%? Is that right that Farrah Paul's perhaps assumptions have changed? Any impact from VBP or base impact that we should be aware of? And what are you assuming for pricing in fiscal year 24? Thank you."
            },
            {
                "analyst_name": "Danielle Antelfi",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Gennar Osantanathan",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Richard Newitter",
                "level": 1,
                "quoted_compliment": "Hi. Thanks for taking the questions, and congrats on a really strong finish to the year. Thanks. My first question is just going back to TAVR. You know, at your analyst day, you had talked to, you know, an expectation and a level of confidence that you could disrupt that market in the U.S. relatively quickly out of the gate. I'm just curious with, you know, I get something approaching 20% share of the market over time, which is what you've done you know, in other markets with your disruption capabilities. I'm just curious, does anything change there with the indeterminate kind of view of what the next steps are for the U.S.? I'm just trying to focus on that commentary a bit. You know, does your outlook for the franchise in the U.S. change in TAVR? And then I have a follow-up."
            },
            {
                "analyst_name": "Josh Jennings",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Patrick Wood",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Michael Pollark",
                "level": 0,
                "quoted_compliment": ""
            }
        ]
    },
    "2024_Q1": {
        "year": 2024,
        "quarter": 1,
        "date": "2024-04-24T08:00:00-04:00",
        "compliments": [
            {
                "analyst_name": "Robbie Marcus",
                "level": 1,
                "quoted_compliment": "Oh, great. Thanks for taking the question. Congrats on a fantastic quarter. Thanks, Robbie. I guess with my one question, it has to be on Farrapulse and EP in general. The beat was substantial, both US and OUS. The doc feedback we hear is phenomenal on Farrapulse, PFA in general. I'd just love to get your view on what you're seeing in the field, the willingness to adopt the new technology, how fast it could go, and how much of the guidance raised is just from Farrapulse here and the opportunity. Thanks a lot."
            },
            {
                "analyst_name": "Larry Beagleson",
                "level": 1,
                "quoted_compliment": "Good morning. I'll echo Robbie's congratulations on a really strong quarter here. Just with my one question, I feel compelled to ask a big-picture question here. You updated your LRP in September of last year to 8% to 10% organic growth for 2024 to 2026. The assumption at the time was that growth in 2025 would accelerate over 2024. You're guiding today to 10% to 12% organic growth. So the question is, do you still expect growth to accelerate in 2025? And how should we think about the 8% to 10% CAGR in the context to this strong 2024 guidance? Thanks for taking the question."
            },
            {
                "analyst_name": "Rick Wise",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Joanne Winch",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Vijay Kumar",
                "level": 1,
                "quoted_compliment": "Hey guys, thanks for taking my question and congrats on a really solid print share. Mike, maybe one question on the EP portfolio. the 70% overall growth, 85% U.S., can you give us a little bit of color on, was there any stocking dynamic? How much of this was driven by the account of openings versus that procedure uptake? And sort of related to that, does new tech add-on payment, does it matter where we're on TPG? Thank you."
            },
            {
                "analyst_name": "Travis Steed",
                "level": 1,
                "quoted_compliment": "Hey, everybody. Congrats again on the good quarter. I wanted to ask about the new DRG for ablation and left atrial appendage closure and the overall LAC market. Do you think that market can kind of sustain this 20% plus growth through before the indication extensions, or do you kind of need to see those indication extensions at some point sooner rather than later?"
            },
            {
                "analyst_name": "Danielle Antelfi",
                "level": 1,
                "quoted_compliment": "Hey, good morning, everyone. Thanks so much for taking the questions. I'll also say congrats on a really strong quarter. For my one question, I wanted to look at some of the, I'll call them legacy businesses. Not sure if that's fair to describe them, maybe slower growth businesses. I mean, a CRM mid-single-digit growth is very strong. Interventional cardiology of double digits, very strong. Just curious about how to think about those sort of slower growth in interventional cardiology. I'm thinking more on the drug-eluting stem portfolio, obviously, and then CRM. Can they sustain these kinds of growth profiles, given that the end markets are, from a volume perspective, are arguably probably some of your slower growth end markets? And what needs to happen from an innovation perspective to sustain that sort of growth? Thanks so much."
            },
            {
                "analyst_name": "Josh Jennings",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Chris Pasquale",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Matthew O'Brien",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Matt Taylor",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Matt Mixick",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Michael Pollack",
                "level": 0,
                "quoted_compliment": ""
            }
        ]
    },
    "2024_Q2": {
        "year": 2024,
        "quarter": 2,
        "date": "2024-07-24T08:00:00-04:00",
        "compliments": [
            {
                "analyst_name": "Robbie Marcus",
                "level": 1,
                "quoted_compliment": "Oh, thank you, and congratulations on another fantastic quarter here. Thanks, Robbie."
            },
            {
                "analyst_name": "Joanne Wunsch",
                "level": 1,
                "quoted_compliment": "Thank you so much for taking the question, and I echo. A very nice quarter. Can we unpack just a little bit, and you may not like this question, but I get it a lot. What's next? And how do we think about, to your point, we're going to talk about therapist and launchment a lot, but people are now sort of looking forward at how does this continue to roll out to deliver this kind of growth? And thank you."
            },
            {
                "analyst_name": "Larry Beagleson",
                "level": 1,
                "quoted_compliment": "Good morning. Thanks for taking the question, and congrats on a really nice quarter here. Mike, maybe just to drill down on EP and Farrah Pulse. I guess it's a similar question, but just the sustainability here of the growth and the share. By our math, it looks like you've captured about 15% of the US EP market in the second quarter, excluding Bayless. Help us understand how durable your EP share and growth is. Can EP continue to be a growth driver for Boston Scientific for years to come And what's driving your confidence you can compete effectively with, you know, Athera and Varipulse when they launch? Thank you."
            },
            {
                "analyst_name": "Rick Wise",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Vijay Kumar",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "David Roman",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Patrick Wood",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Travis Steed",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Josh Jennings",
                "level": 1,
                "quoted_compliment": "Good morning. Thanks a lot for taking the questions and congrats on the stellar results. I wanted to just follow up on Travis's two questions. I guess first on TAVR, could we see top line data before the ACC presentation next year and could Boston file before that presentation? And then just the other follow-up is just on the profitability. You guys are seeing, letting a lot of profitability flow through on the outperformance on the top line. Wanted to just get a sense of of taking some of that profitability and reinvesting that, you know, where could we see, where's some of those dollars going, and just some high-level commentary on that reinvestment driving, supporting this sustainability of top-tier revenue growth in the medtech space. Thanks for taking the questions."
            },
            {
                "analyst_name": "Danielle Antelfi",
                "level": 1,
                "quoted_compliment": "Hey, good morning, everyone. Thanks so much for taking the question, and I'll be a broken record here. Congrats on the really awesome quarter. Mike, I wanted to go in a different direction here, away from PFA for a second, and talk about how we should think, just on this theme of sustainability of growth into 2025, appreciating we won't give guidance here, but if we think about Asian DCB launching back half of this year and modular development, in the back half, or I guess is that launching this year as well. So how do we think about those contributing and maybe elevating CRM growth above the market in next year as well as the interventional cardiology portfolio? Thanks so much."
            },
            {
                "analyst_name": "Unknown",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Matt Taylor",
                "level": 1,
                "quoted_compliment": "Hi. Good morning, guys. Thank you for taking the question. Congrats on the great quarter. I did want to ask a follow-up question on Farrakhal just to help with thinking about the modeling and the opportunity there. Could you give us any kind of update or parameters on on how many centers you're in, how many boxes you've placed, and maybe talk about whether the early experience has changed your views on how the market could evolve like you laid out at the analyst day several months ago."
            }
        ]
    },
    "2024_Q3": {
        "year": 2024,
        "quarter": 3,
        "date": "2024-10-23T08:00:00-04:00",
        "compliments": [
            {
                "analyst_name": "Robbie Marcus",
                "level": 1,
                "quoted_compliment": "Oh, great. Good morning, and congrats on another fantastic quarter here. Thanks, Rob. My one question, there's so much to ask about here. Make it a good one, Robby. In our checks, we hear consistently that the upcoming option trial that we'll see at AHA combined with the recently started on October 1st, reimbursement for concomitant, watchman, and ablation, has already started to kick into gear, and option could meaningfully alter the usage patterns ahead of Champion in the first half of 26. So I wanted to get your thoughts on the importance of both concomitant and should option be positive, what that can mean for both of those franchises, both in the short and long term. Thanks."
            },
            {
                "analyst_name": "Joanne Lynch",
                "level": 1,
                "quoted_compliment": "Good morning, and thank you for the question. I want to talk about the amazing results of Faribault that we just saw, and specifically how you're thinking about moving, I was really interested in one quote that you said, to exceed 40 to 60% of global AF procedures by 2026. Thank you."
            },
            {
                "analyst_name": "Larry Diegelson",
                "level": 1,
                "quoted_compliment": "Good morning. Thanks for taking the question. I'll echo my congratulations on a really phenomenal quarter here. You know, Dr. Stein, given the importance of Faribulse, can you provide more color on the Avant Garde trial and the observations you saw? And, you know, related to that, there are going to be more PFA ablation choices soon, including from the market leader. You know, once these new PFA catheters are launched, what are the factors that will lead existing Farapulse customers to stay with Farapulse or choose Farapulse if they haven't adopted it yet? Thank you."
            },
            {
                "analyst_name": "Rick Wise",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "David Roman",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Matt Mixick",
                "level": 1,
                "quoted_compliment": "Hey, thanks so much for fitting us in, and congrats on a really impressive quarter and all the great growth drivers you have running. I had a question just on, maybe for Dan, on some of the dynamics in the gross margin line in the quarter. You mentioned FX being kind of one of the primary headwinds, but as you move into 25, maybe you can talk a little bit about you know, where the leverage in the model is. It's, you know, table gross margin and levering some of the operating investments that you're making, but maybe just some color on how you see that progressing at this point. Thanks."
            },
            {
                "analyst_name": "Travis Steed",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Danielle Antelfi",
                "level": 1,
                "quoted_compliment": "Hey. Good morning, everyone. Thanks so much for taking the question. Congrats on this amazing quarter. I'm kind of speechless. Just wanted to ask, I appreciate there's not going to be a lot. You can say, Dan, appreciate the comments that you did give on 2025, but specifically as we think about sales, you noted above market sales growth. I mean, market can be a moving target a little bit here about how you think about the markets growing next year. So I was hoping maybe you could give a little bit more color if possible, even if it's just highlighting tailwinds and headwinds from a sales growth perspective to think about as we look ahead to 2025. Thanks so much."
            },
            {
                "analyst_name": "Anthony Patron",
                "level": 1,
                "quoted_compliment": "Well, thanks and congrats on a strong quarter here. I think the question will be on the go-to market next year, 2025. You go back to the October 18th press release and you have Farrow Wave Navcatheter out there, but it indicates that it's exclusive to Opal on the mapping side. So in other words, the company is coming with a closed loop offering here next year and presumably we'll have competitors that are coming with a bundled approach So maybe the question here is just when we enter 25, it seems that three competitors will be out there with a bundled approach to PFA with mappers. So maybe just walk through that dynamic a little bit. Congratulations again on the quarter."
            },
            {
                "analyst_name": "Vijay Kumar",
                "level": 1,
                "quoted_compliment": "Hi, guys. Congrats on a nice quarter here, and thanks for taking my question. Mike, maybe one for you on next week's accurate NEO2 results here. What is the regulatory strategy? Do you expect to file with the FDA? And I think you mentioned that you expect to have a successful launch in the U.S. Is that referring to NEO2 or some other generation of the valve? So maybe talk about your TAVR strategy in the U.S.? ?"
            },
            {
                "analyst_name": "Josh Jennings",
                "level": 0,
                "quoted_compliment": ""
            },
            {
                "analyst_name": "Matthew O'Brien",
                "level": 0,
                "quoted_compliment": ""
            }
        ]
    }
}